Smiths Medical announced today that it partnered with Ivenix on infusion management. Minneapolis-based Smiths Medical will invest an unspecified amount in the long-term partnership to “revolutionize” infusion management and improve patient safety while meeting the needs of healthcare providers, according to a news release. Boston-based Ivenix develops what it touts as “the first and only […]
Gyroscope Therapeutics launches IPO roadshow
Gyroscope Therapeutics announced today that it launched the roadshow for its initial public offering of nearly 7 million shares. London-based Gyroscope’s U.S. offering includes up to 6.75 million American Depository Shares (ADSs) representing 6.75 million ordinary shares, according to a news release. Gyroscope expects pricing for the IPO to range between $20 and $22 per […]
FDA approves higher dosage of naloxone nasal spray
The FDA announced today that it approved a higher dose of naloxone hydrochloride nasal spray to treat opioid overdose. Previously, the FDA had approved 2 mg and 4 mg naloxone nasal spray products, but the newly approved product — Kloxxado from Hikma Pharmaceuticals — delivers 8 mg of naloxone into the nasal cavity, according to […]
Bexson Biomedical wins U.S. patent for ketamine formulation
Bexson Biomedical announced that the U.S. Patent and Trademark Office (USPTO) granted a patent for its BB106 ketamine therapy. Santa Barbara, Calif.-based Bexson’s patent describes pharmaceutical formulations and treatment methods for the ketamine therapy, which the company believes allows for safety, comfort and pharmacokinetics that improve the administration of ketamine through multiple avenues, including the […]
Dexcom dips after hours despite Street-beating Q1, raised guidance
Dexcom (NSDQ:DXCM) shares took a hit after hours today despite first-quarter results that beat the consensus forecast. DXCM shares were down -5.2% at $400 per share after hours. MassDevice’s MedTech 100 Index — which includes stocks of the world’s largest medical device companies — was down -0.8%. The San Diego-based glucose monitoring technology developer posted […]
Vascular Therapies touts surgical stenosis treatment trial despite missed primary endpoint
Vascular Therapies announced today that a Phase 3 clinical trial of its Sirogen sirolimus formulation showed encouraging outcomes. Cresskill, N.J.-based Vascular Therapies designed its Sirogen proprietary sirolimus formulation for intraoperative local drug delivery to reduce surgical stenosis in blood vessels. The Phase 3 clinical trial evaluated Sirogen in elderly end-stage renal disease patients, according to […]
West Pharmaceutical Services beats Street in Q1, raises guidance
West Pharmaceutical Services (NYSE:WST) posted Street-beating first-quarter financial results and raised its full-year guidance for 2021. The Exton, Pa.-based company posted profits of $151.2 million, or $1.99 per share, on sales of $670.7 million for the three months ended March 31, 2021, more than doubling its bottom-line on sales growth of 36.5%. Adjusted to exclude […]
Merck comes up short on Q1 forecast
Merck (NYSE:MRK) shares took a hit before hours today on first-quarter results that missed the consensus forecast. The Kenilworth, N.J.-based company posted profits of $3.2 billion, or $1.25 per share, on sales of $12.1 billion for the three months ended March 31, 2021, for a -1.2% bottom-line slide on revenues that remained almost identical year-over-year. […]
Teva Pharmaceuticals unchanged before hours on Q1 earnings beat
Teva Pharmaceuticals (NYSE:TEVA) shares stood firm before hours today on first-quarter earnings that topped the consensus forecast. The Tel Aviv, Israel-based company posted profits of $84 million, or 7¢ per share, on sales of $4 billion for the three months ended March 31, 2021, for a more-than tripled bottom-line despite a sales decline of -8.6%. […]
Canada approves J&J Vision’s drug-eluting contact lens
Johnson & Johnson Vision announced today that it received Health Canada approval for its Acuvue Theravision drug-eluting contact lens. Jacksonville, Fla.-based J&J Vision’s Acuvue Theravision with Ketotifen is touted as the first and only vision-correcting contact lens that relieves allergic eye itch through drug delivery. The company received Japanese approval for the lens last month. […]
